At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, John Gribben, MD, DSc, and Stephan Stilgenbauer, MD, discuss drug combination approaches in chronic lymphocytic leukemia (CLL) therapy. Targeting multiple molecules or pathways may have the potential to improve treatment response.